AZN - AstraZeneca PLC
| Previous Close | 40.95 |
| Open | 41.18 |
| Bid | 41.39 x 1300 |
| Ask | 41.40 x 1800 |
| Day's Range | 41.15 - 41.45 |
| 52 Week Range | 34.38 - 43.30 |
| Volume | 850,244 |
| Avg. Volume | 4,751,317 |
| Market Cap | 110.824B |
| Beta (3Y Monthly) | 0.45 |
| PE Ratio (TTM) | 43.56 |
| EPS (TTM) | 0.95 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.75%) |
| Ex-Dividend Date | 2019-02-28 |
| 1y Target Est | 45.10 |
- Yahoo Finance Video•14 days ago
How Merck reached new ground in the fight against cancer
A major break through in the fight against lung cancer. Merck announced that its drug Keytruda has shown an increase in the survival for those suffering from lung cancer. Merck CFO Rob Davis talks with Yahoo Finance's Adam Shapiro and Julie Hyman.
- Market Realist•yesterday
How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.
- Zacks•yesterday
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
- Market Realist•yesterday
AstraZeneca’s Lynparza Continues to Dominate
In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.
- Reuters•yesterday
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said. BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.
- Reuters•yesterday
UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.
- Market Realist•2 days ago
Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.
- Market Realist•2 days ago
How Are AstraZeneca’s Revenues Trending in 2019?
On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.
- Market Realist•2 days ago
What Analysts Recommend for Merck and AstraZeneca in June
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
- Zacks•2 days ago
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
- Business Wire•4 days ago
CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
- Insider Monkey•5 days ago
Is AstraZeneca plc (AZN) A Good Stock To Buy?
At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]
- Zacks•5 days ago
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
- Business Wire•5 days ago
LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo
- Zacks•6 days ago
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
Here are five reasons why investors may consider betting on Merck (MRK) stock
- Zacks•9 days ago
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
- Business Wire•9 days ago
FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes
FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58
- Simply Wall St.•9 days ago
What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?
A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will...
- InvestorPlace•12 days ago
New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.
- Zacks•12 days ago
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
- Zacks•12 days ago
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
- Zacks•13 days ago
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
- Zacks•14 days ago
Cancer-Fighting Stocks & ETF: What You Need to Know
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
- Zacks•14 days ago
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
- Zacks•14 days ago
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
